Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Blueprint Medicines stock

BPMC
US09627Y1091
A14SDD

Price

96.03
Today +/-
+2.05
Today %
+2.27 %

Blueprint Medicines stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Blueprint Medicines stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Blueprint Medicines stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Blueprint Medicines stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Blueprint Medicines's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Blueprint Medicines Stock Price History

DateBlueprint Medicines Price
11/26/202496.03 undefined
11/25/202493.87 undefined
11/22/202494.15 undefined
11/21/202496.62 undefined
11/20/202494.81 undefined
11/19/202494.60 undefined
11/18/202490.18 undefined
11/15/202488.69 undefined
11/14/202495.65 undefined
11/13/202499.69 undefined
11/12/202496.62 undefined
11/11/202499.87 undefined
11/8/2024100.83 undefined
11/7/2024101.39 undefined
11/6/202499.63 undefined
11/5/202497.55 undefined
11/4/202491.88 undefined
11/1/202490.70 undefined
10/31/202487.51 undefined
10/30/202489.24 undefined
10/29/202483.40 undefined
10/28/202482.77 undefined

Blueprint Medicines Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Blueprint Medicines, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Blueprint Medicines from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Blueprint Medicines’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Blueprint Medicines. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Blueprint Medicines’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Blueprint Medicines’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Blueprint Medicines’s growth potential.

Blueprint Medicines Revenue, EBIT and net profit per share

DateBlueprint Medicines RevenueBlueprint Medicines EBITBlueprint Medicines Net Income
2029e1.49 B undefined0 undefined563.33 M undefined
2028e1.32 B undefined478.77 M undefined475.64 M undefined
2027e1.17 B undefined309.43 M undefined298.41 M undefined
2026e959.83 M undefined119.6 M undefined110.27 M undefined
2025e723.08 M undefined-78.71 M undefined-61.59 M undefined
2024e518.93 M undefined-229.03 M undefined-63.42 M undefined
2023249.38 M undefined-486.28 M undefined-506.98 M undefined
2022204 M undefined-537.5 M undefined-557.5 M undefined
2021180.1 M undefined-642 M undefined-644.1 M undefined
2020793.7 M undefined308.7 M undefined313.9 M undefined
201966.5 M undefined-361.3 M undefined-347.7 M undefined
201844.5 M undefined-247 M undefined-236.6 M undefined
201721.4 M undefined-151.2 M undefined-148.1 M undefined
201627.8 M undefined-72.6 M undefined-72.5 M undefined
201511.4 M undefined-51.6 M undefined-55.9 M undefined
20140 undefined-39.7 M undefined-46.1 M undefined
20130 undefined-21 M undefined-23.8 M undefined

Blueprint Medicines Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000.010.030.020.040.070.790.180.20.250.520.720.961.171.321.49
---145.45-22.22109.5250.001,101.52-77.3013.3322.06108.0339.5832.6422.2112.8012.48
--2,181.82888.891,142.86545.45363.64100.0090.0091.1896.3946.3333.2025.0320.4818.1516.14
0000000793162186240000000
-23-46-55-72-148-236-347313-644-557-506-63-61110298475563
-100.0019.5730.91105.5659.4647.03-190.20-305.75-13.51-9.16-87.55-3.17-280.33170.9159.4018.53
25.825.818.227.537.843.947.856.258.559.660.56000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Blueprint Medicines Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Blueprint Medicines is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20132014201520162017201820192020202120222023
                     
247.2162.7214.2673.4494483.6871.8477.1945710.64
003.43.600.223.425.33736.943.18
00000000000
00000008.621.829.721.22
0.514.32.712.15.69.82218.13533.35
00.050.170.220.690.50.520.930.551.050.81
1.41.56.76.224.429.6111.1101.7120.9115.2115.65
00054.10064.4677.9557.5133.556.53
00000000000
00000000000
00000000000
0.30.21.82.15.910.715.411.119.854.668.68
1.71.78.562.430.340.3190.9790.7698.2303.3240.86
00.050.180.280.720.540.711.721.251.351.05
                     
40114.8000000.10.10.10.06
000.280.420.981.021.412.112.252.362.47
-41.9-82.2-135-207.5-355.6-597.5-945.2-631.4-1,275.4-1,833-2,339.94
0000-0.3-0.2-2.5-5.2-4.1-10.4-3.5
00000000000
-00.040.140.210.620.420.461.470.970.510.13
1.40.82.52.23.73.34.84.48.32.74.71
0.93.86.411.730.551.795.5113.9129.9141.7139.93
0.20.46.5127.15.36.212.611.52240.01
00000000000
0.71.73.32.61.5000016.930.28
3.26.718.728.542.860.3106.5130.9149.7183.3214.92
2.27.34.11.500000122.2208.54
00000000000
0.30.412.239.748.960.8136.9117.5131.7529.8495.18
2.57.716.341.248.960.8136.9117.5131.7652703.72
5.714.43569.791.7121.1243.4248.4281.4835.3918.64
00.050.180.280.720.540.711.721.251.351.05
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Blueprint Medicines provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Blueprint Medicines's financial health and stability.

Assets

Blueprint Medicines's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Blueprint Medicines must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Blueprint Medicines after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Blueprint Medicines's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-20-40-52-72-148-236-347313-644-557-506
0001145661111
00000000000
11143914319-15-23-53-41
0410122456109157454196192
000000000938
00000000060
-19-35-31-24-119-175-278387-298-502-436
00-4-2-15-12-14-3-3-8-16
00-6-218-75-161-16-434-225-149274
00-1-216-60-148-2-431-222-140290
00000000000
36-1-3-2-100013797
1575157136547634161750821
1881153132543434061750561119
00-20-100004150
00000000000
-145115-110348-33146570-474-90-43
-19.3-36.1-36.6-26.9-135.4-187.7-292383.8-301.8-511.2-452.91
00000000000

Blueprint Medicines stock margins

The Blueprint Medicines margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Blueprint Medicines. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Blueprint Medicines.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Blueprint Medicines's sales revenue. A higher gross margin percentage indicates that the Blueprint Medicines retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Blueprint Medicines's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Blueprint Medicines's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Blueprint Medicines's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Blueprint Medicines. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Blueprint Medicines's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Blueprint Medicines Margin History

Blueprint Medicines Gross marginBlueprint Medicines Profit marginBlueprint Medicines EBIT marginBlueprint Medicines Profit margin
2029e96.58 %0 %37.88 %
2028e96.58 %36.22 %35.98 %
2027e96.58 %26.4 %25.46 %
2026e96.58 %12.46 %11.49 %
2025e96.58 %-10.89 %-8.52 %
2024e96.58 %-44.13 %-12.22 %
202396.58 %-194.99 %-203.3 %
202291.27 %-263.48 %-273.28 %
202190.01 %-356.47 %-357.63 %
202099.95 %38.89 %39.55 %
201996.58 %-543.31 %-522.86 %
201896.58 %-555.06 %-531.69 %
201796.58 %-706.54 %-692.06 %
201696.58 %-261.15 %-260.79 %
201596.58 %-452.63 %-490.35 %
201496.58 %0 %0 %
201396.58 %0 %0 %

Blueprint Medicines Stock Sales Revenue, EBIT, Earnings per Share

The Blueprint Medicines earnings per share therefore indicates how much revenue Blueprint Medicines has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Blueprint Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Blueprint Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Blueprint Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Blueprint Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Blueprint Medicines Revenue, EBIT and net profit per share

DateBlueprint Medicines Sales per ShareBlueprint Medicines EBIT per shareBlueprint Medicines Earnings per Share
2029e23.41 undefined0 undefined8.87 undefined
2028e20.81 undefined0 undefined7.49 undefined
2027e18.45 undefined0 undefined4.7 undefined
2026e15.11 undefined0 undefined1.74 undefined
2025e11.38 undefined0 undefined-0.97 undefined
2024e8.17 undefined0 undefined-1 undefined
20234.12 undefined-8.03 undefined-8.37 undefined
20223.42 undefined-9.02 undefined-9.35 undefined
20213.08 undefined-10.97 undefined-11.01 undefined
202014.12 undefined5.49 undefined5.59 undefined
20191.39 undefined-7.56 undefined-7.27 undefined
20181.01 undefined-5.63 undefined-5.39 undefined
20170.57 undefined-4 undefined-3.92 undefined
20161.01 undefined-2.64 undefined-2.64 undefined
20150.63 undefined-2.84 undefined-3.07 undefined
20140 undefined-1.54 undefined-1.79 undefined
20130 undefined-0.81 undefined-0.92 undefined

Blueprint Medicines business model

Blueprint Medicines Corp is a biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company was founded in 2008 by a team of experts in the field of molecular biology, biochemistry, and cancer research and is headquartered in Cambridge, Massachusetts, USA. History Blueprint Medicines started as a spin-off from the Broad Institute of MIT and Harvard, a partnership between the Massachusetts Institute of Technology and Harvard University. The founders' goal was to develop a new type of drugs based on the genetic cause of diseases, rather than just treating symptoms. In 2016, the company went public and has since experienced rapid growth. Blueprint Medicines has generated significant revenue through the sale of its products as well as through licensing agreements with other companies. Business model Blueprint Medicines aims to play a leading role in the development of novel drugs based on the identification and treatment of gene mutations. The company utilizes a combination of computer technology, molecular biology, chemistry, and clinical research to specifically target the causes of diseases. Blueprint Medicines has three main areas of focus: 1. Oncology The main focus of Blueprint Medicines is cancer research. The company has several drugs in development that specifically target mutations associated with certain types of cancer. These drugs aim to improve the effectiveness of cancer treatment and enhance patients' quality of life. 2. Blue Flag Technology Blueprint Medicines has developed a proprietary technology called Blue Flag, which allows the company to rapidly and accurately identify and characterize specific mutations in genes. This technology is key to the development of precision medicine approaches tailored to the specific needs of patients. 3. Rare diseases Blueprint Medicines also has a commitment to developing drugs for the treatment of rare diseases. The company collaborates with patients, physicians, and patient organizations to develop drugs that meet the needs of patients with rare diseases. Products Blueprint Medicines has brought several products to market and is working on developing additional products. Here are some of the key products: 1. Ayvakit Ayvakit is a drug for the treatment of gastrointestinal stromal tumors (GIST) associated with a specific genetic mutation. The drug has proven to be highly effective and has been approved by the U.S. Food and Drug Administration (FDA). 2. Gavreto Gavreto is a drug for the treatment of adult patients with a specific genetic mutation associated with non-small cell lung cancer. The drug is being developed in collaboration with pharmaceutical company Roche. 3. Pralsetinib Pralsetinib is a drug for the treatment of patients with a specific gene mutation associated with thyroid cancer. The drug has proven to be highly effective and has been approved by the U.S. FDA. Conclusion Blueprint Medicines Corp is an emerging biotechnology company that focuses on the discovery, development, and commercialization of drugs for the treatment of genetic diseases. The company has established itself as a leader in the field of personalized medicine and has brought several highly effective products to market. Blueprint Medicines continues to work on developing innovative treatment methods for rare diseases and aims to solidify its position as a leading provider of personalized drugs in the global healthcare market. Blueprint Medicines is one of the most popular companies on Eulerpool.com.

Blueprint Medicines SWOT Analysis

Strengths

  • Advanced technology platform and expertise in precision medicine.
  • Strong intellectual property portfolio and extensive research capabilities.
  • Well-established partnerships with pharmaceutical companies.

Weaknesses

  • Limited product portfolio with a focus on specific rare diseases.
  • Vulnerability to changes in regulatory environment and healthcare policies.
  • Reliance on external funding sources for research and development.

Opportunities

  • Growing demand for precision medicines targeting genetic mutations.
  • Potential for strategic collaborations and expansion into new markets.
  • Increasing adoption of personalized medicine approaches globally.

Threats

  • Intense competition from larger pharmaceutical companies.
  • Regulatory challenges and lengthy approval processes for new drugs.
  • Potential risks associated with clinical trials and adverse events.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Blueprint Medicines Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Blueprint Medicines historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Blueprint Medicines shares outstanding

The number of shares was Blueprint Medicines in 2023 — This indicates how many shares 60.558 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Blueprint Medicines earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Blueprint Medicines's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Blueprint Medicines’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Blueprint Medicines's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Blueprint Medicines.

Blueprint Medicines latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.99 -0.89  (9.73 %)2024 Q3
6/30/2024-1.32 -0.8  (39.24 %)2024 Q2
3/31/2024-1.7 -1.32  (22.15 %)2024 Q1
12/31/2023-2.08 -1.82  (12.53 %)2023 Q4
9/30/2023-2.41 -2.2  (8.88 %)2023 Q3
6/30/2023-2.59 -2.19  (15.46 %)2023 Q2
3/31/2023-2.72 -2.15  (21.05 %)2023 Q1
12/31/2022-2.7 -2.65  (1.95 %)2022 Q4
9/30/2022-2.54 -2.23  (12.08 %)2022 Q3
6/30/2022-2.27 -2.68  (-17.97 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Blueprint Medicines stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees56
Percentage of women in management
Percentage of Asian employees24
Share of Asian management
Percentage of Hispanic/Latino employees5
Hispano/Latino Management share
Percentage of Black employees6
Black Management Share
Percentage of white employees64
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Blueprint Medicines shareholders

%
Name
Stocks
Change
Date
10.27223 % The Vanguard Group, Inc.6,525,949227,9016/30/2024
9.11696 % T. Rowe Price Associates, Inc.5,792,006-376,7586/30/2024
7.48281 % BlackRock Institutional Trust Company, N.A.4,753,827180,6786/30/2024
6.23384 % Fidelity Management & Research Company LLC3,960,359-198,4466/30/2024
5.09296 % Wellington Management Company, LLP3,235,555-939,5976/30/2024
3.87284 % Rock Springs Capital Management LP2,460,417-38,0316/30/2024
3.74608 % State Street Global Advisors (US)2,379,884187,1826/30/2024
2.50892 % William Blair Investment Management, LLC1,593,916-114,1326/30/2024
2.29731 % Geode Capital Management, L.L.C.1,459,48488,3576/30/2024
2.06527 % Macquarie Investment Management1,312,0678296/30/2024
1
2
3
4
5
...
10

Blueprint Medicines Executives and Management Board

Ms. Kathryn Haviland

(47)
Blueprint Medicines President, Chief Executive Officer, Director (since 2016)
Compensation 6.22 M

Mr. Percy Carter

(52)
Blueprint Medicines Chief Scientific Officer
Compensation 4.38 M

Dr. Christopher Murray

(60)
Blueprint Medicines Executive Vice President, Chief Technical Operations and Quality Officer
Compensation 3.54 M

Dr. Fouad Namouni

(54)
Blueprint Medicines President - Research and Development
Compensation 2.81 M

Ms. Christina Rossi

(47)
Blueprint Medicines Chief Operating Officer
Compensation 2.77 M
1
2
3
4
...
5

Blueprint Medicines Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Catalent Stock
Catalent
SupplierCustomer0,920,340,540,860,880,49
Certara Stock
Certara
SupplierCustomer0,780,640,820,880,87
Zai Lab Stock
Zai Lab
SupplierCustomer0,370,660,260,800,52
CStone Pharmaceuticals Stock
CStone Pharmaceuticals
SupplierCustomer0,210,320,150,690,72
Ipsen Stock
Ipsen
SupplierCustomer0,160,730,88-0,62-0,67-0,70
Roche Holding Stock
Roche Holding
SupplierCustomer-0,060,610,140,23-0,04-0,34
1

Most common questions regarding Blueprint Medicines

What values and corporate philosophy does Blueprint Medicines represent?

Blueprint Medicines Corp is a biopharmaceutical company that focuses on delivering transformative therapies for patients. The company is driven by a clear set of values and corporate philosophy. Blueprint Medicines Corp stands for innovation, collaboration, and a strong commitment to patients and their families. With a team of dedicated professionals, the company strives to make a meaningful impact on patients' lives by advancing precision medicine. By leveraging their expertise in genomics, Blueprint Medicines Corp aims to develop highly selective medicines to target genetic drivers of disease. Through their relentless pursuit of excellence, the company seeks to redefine the treatment landscape and provide hope for patients in need.

In which countries and regions is Blueprint Medicines primarily present?

Blueprint Medicines Corp is primarily present in the United States.

What significant milestones has the company Blueprint Medicines achieved?

Blueprint Medicines Corp has achieved several significant milestones. The company received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for its drug, Ayvakit, to treat certain types of advanced gastrointestinal stromal tumors (GIST). In the same year, Blueprint Medicines Corp also obtained FDA approval for its drug, Gavreto, to treat metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. These approvals signify the company's progress in developing targeted therapies for oncology patients. Additionally, Blueprint Medicines Corp has collaborated with various pharmaceutical companies to expand its research and development efforts, further establishing itself as a leader in precision medicine.

What is the history and background of the company Blueprint Medicines?

Blueprint Medicines Corp is a leading biopharmaceutical company that focuses on developing highly targeted therapies for genomically defined diseases. Founded in 2008, Blueprint Medicines Corp has a rich history in precision medicine, utilizing a deep understanding of genomics to identify and address the underlying genetic drivers of various diseases. The company has built a strong portfolio of investigational drugs that target specific genetic abnormalities, with a particular emphasis on cancers, rare diseases, and immunological disorders. Through its innovative approach, Blueprint Medicines Corp aims to bring transformative treatments to patients in need, driving advancements in personalized medicine and improving clinical outcomes.

Who are the main competitors of Blueprint Medicines in the market?

The main competitors of Blueprint Medicines Corp in the market include companies such as Amgen, Novartis, and Pfizer.

In which industries is Blueprint Medicines primarily active?

Blueprint Medicines Corp is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Blueprint Medicines?

Blueprint Medicines Corp's business model revolves around developing targeted therapies for genetically defined diseases. The company focuses on precision medicines that target the root cause of diseases at a molecular level. Blueprint Medicines combines deep understanding of disease biology with advanced scientific techniques to identify and develop therapeutics that address unmet medical needs. By leveraging their proprietary research platform and strong scientific expertise, the company aims to discover and advance multiple drug candidates, ultimately delivering transformative treatments to patients. Blueprint Medicines Corp's business model prioritizes innovation, scientific rigor, and strategic partnerships to improve patient outcomes in areas such as oncology and rare genetic disorders.

What is the P/E ratio of Blueprint Medicines 2024?

The Blueprint Medicines P/E ratio is -91.69.

What is the P/S ratio of Blueprint Medicines 2024?

The Blueprint Medicines P/S ratio is 11.21.

What is the Quality Investing of Blueprint Medicines?

The Quality Investing for Blueprint Medicines is 3/10.

What is the revenue of Blueprint Medicines 2024?

The expected Blueprint Medicines revenue is 518.93 M USD.

How high is the profit of Blueprint Medicines 2024?

The expected Blueprint Medicines profit is -63.42 M USD.

What is the business model of Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company specializing in the development of precision medicine for cancer and rare diseases. The company uses a proprietary platform for the discovery and development of kinase inhibitors to identify potential clinical candidates for personalized treatment. The business model of Blueprint Medicines is focused on three main areas: research and development, product commercialization, and partnerships. Research and development is at the core of the business model as the company focuses on developing drugs for indications where existing treatment options are inadequate or nonexistent. The company has a range of products in various stages of clinical development, including Avapritinib, Pralsetinib, AYVAKIT, and GZ/SAR439859. Avapritinib is a kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. Pralsetinib is an oral selective RET inhibitor being developed for the treatment of patients with RET-altered thyroid cancer and non-small cell lung cancer. AYVAKIT is a selective inhibitor of KIT and PDGFRA being developed for the treatment of patients with advanced basal cell carcinoma with KIT and PDGFRA mutations. GZ/SAR439859 is a selective BRAF inhibitor being developed for the treatment of patients with advanced melanoma and other solid tumors. Blueprint Medicines also operates a product commercialization division focused on the marketing and sale of already approved products and products in advanced stages of development. The company has an internal sales team responsible for marketing its products in the United States and also works with partners to sell its products internationally. Partnerships also play a key role in Blueprint Medicines' business model. The company has formed strategic partnerships with leading pharmaceutical and biotechnology companies such as Roche, CStone Pharmaceuticals, and Alexandria Real Estate Equities. These partnerships support the company's commitment to the development of precision medicine and provide access to resources and technologies to further expand its product portfolio. Overall, Blueprint Medicines' business model is focused on the development and commercialization of drugs for the treatment of cancer and rare diseases. The company pursues a comprehensive research and development strategy to identify potential clinical candidates and has a product pipeline focused on various indications. It also operates a product commercialization division and collaborates with leading pharmaceutical and biotechnology companies to build partnerships and sell products internationally.

What is the Blueprint Medicines dividend?

Blueprint Medicines pays a dividend of 0 USD distributed over payouts per year.

How often does Blueprint Medicines pay dividends?

The dividend cannot currently be calculated for Blueprint Medicines or the company does not pay out a dividend.

What is the Blueprint Medicines ISIN?

The ISIN of Blueprint Medicines is US09627Y1091.

What is the Blueprint Medicines WKN?

The WKN of Blueprint Medicines is A14SDD.

What is the Blueprint Medicines ticker?

The ticker of Blueprint Medicines is BPMC.

How much dividend does Blueprint Medicines pay?

Over the past 12 months, Blueprint Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Blueprint Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Blueprint Medicines?

The current dividend yield of Blueprint Medicines is .

When does Blueprint Medicines pay dividends?

Blueprint Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Blueprint Medicines?

Blueprint Medicines paid dividends every year for the past 0 years.

What is the dividend of Blueprint Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Blueprint Medicines located?

Blueprint Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Blueprint Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Blueprint Medicines from 11/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/26/2024.

When did Blueprint Medicines pay the last dividend?

The last dividend was paid out on 11/26/2024.

What was the dividend of Blueprint Medicines in the year 2023?

In the year 2023, Blueprint Medicines distributed 0 USD as dividends.

In which currency does Blueprint Medicines pay out the dividend?

The dividends of Blueprint Medicines are distributed in USD.

All fundamentals about Blueprint Medicines

Our stock analysis for Blueprint Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Blueprint Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.